Quality of Vision questionnaire is comprehensive

Article

The Quality of Vision (QoV) questionnaire enables the comprehensive assessment of the subjective vision quality, claims a study in the journal Optometry and Vision Science.

The Quality of Vision (QoV) questionnaire enables the comprehensive assessment of the subjective vision quality, claims a study in the journal Optometry and Vision Science.

The group managed by Dr Colm McAlinden, School of Medicine, Flinders Medical Centre and Flinders University, Adelaide, South Australia, Australia, gathered data from four studies giving a total of 1930 completed questionnaires. The patient groups included spectacle wearers, contact lens wearers, post-laser refractive surgery, cataract patients and patients who underwent lens implantation surgery.

Three subscales of the questionnaire, frequency, severity and bothersome, were used in conjunction with the Bland-Altman limits of agreement (LoA) to assess interchangeability.

Mean difference, standard deviation of the differences, and the LoA for the frequency compared to the severity subscale were 2.8570, 6.784 and -10.4397 to 16.1537, respectively.

Mean difference, standard deviation and the LoA for frequency compared to bothersome were 5.4674, 12.5768 and -19.1831 to 30.1179, respectively. For the severity compared to the bothersome subscale these values were 2.6104, 9.4444 and -15.9006 to 21.1213, respectively.

The three subscales of the QoV questionnaire were useful for measuring different aspects of quality of vision. Practitioners should use all three subscales of the questionnaire to achieve the most comprehensive results on quality of vision.

The abstract can be found here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.